PL2989088T3 - Pochodne dolastatyny 10 i aurystatyn - Google Patents

Pochodne dolastatyny 10 i aurystatyn

Info

Publication number: PL2989088T3
Authority: PL; Poland
Prior art keywords: auristatins; dolastatin; derivatives
Prior art date: 2013-04-25

Application number

PL14720946T

Other languages

English (en)

Inventor

Michel Perez

Ian Rilatt

Marie Lamothe

Original Assignee

Pierre Fabre Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-25

Filing date

2014-04-25

Publication date

2018-03-30

2014-04-25 Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament

2018-03-30 Publication of PL2989088T3 publication Critical patent/PL2989088T3/pl

Links

OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Crystallography & Structural Chemistry (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL14720946T 2013-04-25 2014-04-25 Pochodne dolastatyny 10 i aurystatyn PL2989088T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR1353793A FR3005051A1 (fr)	2013-04-25	2013-04-25	Derives de la dolastatine 10 et d'auristatines
EP14720946.4A EP2989088B1 (en)	2013-04-25	2014-04-25	Derivatives of dolastatin 10 and auristatins
PCT/EP2014/058427 WO2014174064A1 (en)	2013-04-25	2014-04-25	Derivatives of dolastatin 10 and auristatins

Publications (1)

Publication Number	Publication Date
PL2989088T3 true PL2989088T3 (pl)	2018-03-30

Family

ID=48782433

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18172389T PL3388427T3 (pl)	2013-04-25	2014-04-25	Pochodne dolastatyny 10 i aurystatyn
PL14720946T PL2989088T3 (pl)	2013-04-25	2014-04-25	Pochodne dolastatyny 10 i aurystatyn
PL14719328T PL2989086T3 (pl)	2013-04-25	2014-04-25	Pochodne dolastatyny 10 i aurystatyn

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL18172389T PL3388427T3 (pl)	2013-04-25	2014-04-25	Pochodne dolastatyny 10 i aurystatyn

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL14719328T PL2989086T3 (pl)	2013-04-25	2014-04-25	Pochodne dolastatyny 10 i aurystatyn

Country Status (32)

Country	Link
US (7)	US20160068566A1 (pl)
EP (4)	EP2989086B1 (pl)
JP (3)	JP2016519114A (pl)
KR (4)	KR101640361B1 (pl)
CN (3)	CN105408318A (pl)
AU (3)	AU2014259429A1 (pl)
BR (3)	BR112015026565A2 (pl)
CA (4)	CA2909126A1 (pl)
CY (2)	CY1119677T1 (pl)
DK (3)	DK2989088T3 (pl)
ES (3)	ES2654364T3 (pl)
FR (1)	FR3005051A1 (pl)
HK (1)	HK1215580A1 (pl)
HR (2)	HRP20171977T1 (pl)
HU (3)	HUE035180T2 (pl)
IL (1)	IL242184A (pl)
LT (2)	LT2989086T (pl)
MA (1)	MA38583B1 (pl)
MX (3)	MX2015014831A (pl)
MY (1)	MY177702A (pl)
NO (1)	NO2989088T3 (pl)
NZ (1)	NZ714203A (pl)
PL (3)	PL3388427T3 (pl)
PT (2)	PT2989086T (pl)
RS (2)	RS56717B1 (pl)
RU (3)	RU2662951C2 (pl)
SA (1)	SA515370043B1 (pl)
SI (2)	SI2989088T1 (pl)
TN (2)	TN2015000445A1 (pl)
UA (1)	UA115806C2 (pl)
WO (3)	WO2014174060A1 (pl)
ZA (1)	ZA201508545B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3005051A1 (fr) *	2013-04-25	2014-10-31	Pf Medicament	Derives de la dolastatine 10 et d'auristatines
HUE047952T2 (hu) *	2014-04-25	2020-05-28	Pf Medicament	Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
BR112016024619A2 (pt)	2014-04-25	2017-10-10	Pf Medicament	conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer
WO2016001485A1 (en)	2014-06-30	2016-01-07	Glykos Finland Oy	Saccharide derivative of a toxic payload and antibody conjugates thereof
DK3310800T3 (da)	2015-06-19	2022-02-28	Centurion Biopharma Corp	Leveringssystem til styret lægemiddelfrigivelse
EP3421463A4 (en) *	2016-02-26	2019-10-23	Jiangsu Hengrui Medicine Co., Ltd.	NEW TOXIN AND METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT THEREOF
BR112018016008A2 (pt) *	2016-03-29	2018-12-18	Toray Industries, Inc.	derivado de peptídeo ou o sal farmaceuticamente aceitável do mesmo, conjugado ou um sal farmaceuticamente aceitável do mesmo, e, agente citotóxico.
CN105968038A (zh) *	2016-05-09	2016-09-28	湖北华世通生物医药科技有限公司	二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) *	2016-08-18	2017-02-22	重庆大学	一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) *	2017-06-23	2017-11-07	华东师范大学	一种高立体选择性合成海兔毒素Dap片段的方法
PT3717503T (pt) *	2017-11-30	2024-01-16	Ladrx Corp	Profármacos de ligação a albumina de derivados de auristatina e
KR102858995B1 (ko)	2018-09-27	2025-09-11	피에르 파브르 메디카먼트	설포말레이미드계 링커 및 상응하는 컨쥬게이트
CN110724337B (zh) *	2019-10-16	2022-04-05	江苏德威新材料股份有限公司	一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
CA3230737A1 (en)	2021-09-03	2023-03-09	Toray Industries, Inc.	Pharmaceutical composition for cancer treatment and/or prevention
WO2024213080A1 (zh)	2023-04-12	2024-10-17	荣昌生物制药(烟台)股份有限公司	一种甲基奥瑞他汀e化合物的制备及纯化方法
CN121241045A (zh) *	2023-06-02	2025-12-30	荣昌生物制药(烟台)股份有限公司	一种甲基奥瑞他汀e化合物中间体的制备及纯化方法
CN118165066B (zh) *	2024-02-26	2025-03-21	复旦大学	一种含氟多肽及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2173150C (en) *	1993-10-01	2004-11-30	Kyoichi Sakakibara	Novel peptide derivatives
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
WO2007008603A1 (en) *	2005-07-07	2007-01-18	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
KR101674097B1 (ko) *	2008-04-11	2016-11-08	시애틀 지네틱스, 인크.	췌장, 난소 및 다른 암의 검출 및 치료
EP2403524A4 (en) *	2009-03-06	2012-09-26	Agensys Inc	CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12
CN103200950B (zh) *	2010-06-10	2016-03-16	西雅图基因公司	新颖的耳他汀衍生物及其用途
ES2553874T3 (es) *	2010-09-29	2015-12-14	Seattle Genetics, Inc.	N-Carboxialquil-auristatinas y su uso
CA2813411C (en) *	2010-11-05	2016-08-02	Rinat Neuroscience Corporation	Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP6023097B2 (ja) *	2011-03-16	2016-11-09	シアトルジェネティックス，インコーポレイテッド	Ｎカルボキシアルキルオーリスタチンおよびその使用
AU2012244673A1 (en) *	2011-04-21	2013-11-28	Seattle Genetics, Inc.	Novel binder-drug conjugates (ADCs) and their use
EP2714685B1 (en) *	2011-05-27	2016-10-19	Ambrx, Inc.	Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
KR102179369B1 (ko) *	2011-05-27	2020-11-16	암브룩스, 인코포레이티드	비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
KR102143664B1 (ko) *	2012-06-07	2020-08-11	암브룩스, 인코포레이티드	전립선 특이적 막 항원 항체 약물 접합체
SG11201408494UA (en) *	2012-06-19	2015-02-27	Ambrx Inc	Anti-cd70 antibody drug conjugates
US20150314007A1 (en) *	2012-12-21	2015-11-05	Glykos Finland Oy	Linker-payload molecule conjugates
FR3005051A1 (fr) *	2013-04-25	2014-10-31	Pf Medicament	Derives de la dolastatine 10 et d'auristatines
HUE047952T2 (hu) *	2014-04-25	2020-05-28	Pf Medicament	Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra

2013
- 2013-04-25 FR FR1353793A patent/FR3005051A1/fr not_active Withdrawn
2014
- 2014-04-25 AU AU2014259429A patent/AU2014259429A1/en not_active Abandoned
- 2014-04-25 CA CA2909126A patent/CA2909126A1/en not_active Abandoned
- 2014-04-25 US US14/783,003 patent/US20160068566A1/en not_active Abandoned
- 2014-04-25 PL PL18172389T patent/PL3388427T3/pl unknown
- 2014-04-25 BR BR112015026565A patent/BR112015026565A2/pt not_active IP Right Cessation
- 2014-04-25 BR BR112015026478A patent/BR112015026478A2/pt not_active Application Discontinuation
- 2014-04-25 EP EP14719328.8A patent/EP2989086B1/en active Active
- 2014-04-25 WO PCT/EP2014/058422 patent/WO2014174060A1/en not_active Ceased
- 2014-04-25 DK DK14720946.4T patent/DK2989088T3/en active
- 2014-04-25 KR KR1020157033194A patent/KR101640361B1/ko active Active
- 2014-04-25 HR HRP20171977TT patent/HRP20171977T1/hr unknown
- 2014-04-25 DK DK18172389.1T patent/DK3388427T3/da active
- 2014-04-25 PL PL14720946T patent/PL2989088T3/pl unknown
- 2014-04-25 BR BR112015026410-7A patent/BR112015026410B1/pt not_active IP Right Cessation
- 2014-04-25 MX MX2015014831A patent/MX2015014831A/es unknown
- 2014-04-25 CN CN201480032708.3A patent/CN105408318A/zh active Pending
- 2014-04-25 MY MYPI2015703517A patent/MY177702A/en unknown
- 2014-04-25 HU HUE14720946A patent/HUE035180T2/hu unknown
- 2014-04-25 CA CA2910178A patent/CA2910178A1/en not_active Abandoned
- 2014-04-25 HR HRP20181890TT patent/HRP20181890T1/hr unknown
- 2014-04-25 RS RS20171344A patent/RS56717B1/sr unknown
- 2014-04-25 ES ES14720946.4T patent/ES2654364T3/es active Active
- 2014-04-25 EP EP14719330.4A patent/EP2989087A1/en not_active Withdrawn
- 2014-04-25 RU RU2015149527A patent/RU2662951C2/ru active
- 2014-04-25 LT LTEP14719328.8T patent/LT2989086T/lt unknown
- 2014-04-25 NO NO14720946A patent/NO2989088T3/no unknown
- 2014-04-25 WO PCT/EP2014/058425 patent/WO2014174062A1/en not_active Ceased
- 2014-04-25 JP JP2016509482A patent/JP2016519114A/ja active Pending
- 2014-04-25 MX MX2015014746A patent/MX372911B/es active IP Right Grant
- 2014-04-25 PT PT14719328T patent/PT2989086T/pt unknown
- 2014-04-25 SI SI201430523T patent/SI2989088T1/en unknown
- 2014-04-25 JP JP2016509480A patent/JP6606489B2/ja not_active Expired - Fee Related
- 2014-04-25 US US14/784,163 patent/US20160068567A1/en not_active Abandoned
- 2014-04-25 EP EP18172389.1A patent/EP3388427B1/en active Active
- 2014-04-25 MX MX2015014941A patent/MX345126B/es active IP Right Grant
- 2014-04-25 CA CA2910176A patent/CA2910176C/en active Active
- 2014-04-25 AU AU2014259427A patent/AU2014259427B2/en not_active Ceased
- 2014-04-25 KR KR1020157033192A patent/KR102368136B1/ko not_active Expired - Fee Related
- 2014-04-25 CN CN201480023286.3A patent/CN105143199A/zh active Pending
- 2014-04-25 CN CN201480030093.0A patent/CN105377834B/zh active Active
- 2014-04-25 NZ NZ714203A patent/NZ714203A/en not_active IP Right Cessation
- 2014-04-25 PT PT147209464T patent/PT2989088T/pt unknown
- 2014-04-25 PL PL14719328T patent/PL2989086T3/pl unknown
- 2014-04-25 AU AU2014259431A patent/AU2014259431B2/en not_active Ceased
- 2014-04-25 HK HK16103554.4A patent/HK1215580A1/zh unknown
- 2014-04-25 KR KR1020157033193A patent/KR20160003735A/ko not_active Withdrawn
- 2014-04-25 HU HUE14719328A patent/HUE040431T2/hu unknown
- 2014-04-25 TN TN2015000445A patent/TN2015000445A1/en unknown
- 2014-04-25 ES ES18172389T patent/ES2908224T3/es active Active
- 2014-04-25 DK DK14719328.8T patent/DK2989086T3/en active
- 2014-04-25 US US14/786,921 patent/US20160083420A1/en not_active Abandoned
- 2014-04-25 WO PCT/EP2014/058427 patent/WO2014174064A1/en not_active Ceased
- 2014-04-25 JP JP2016509483A patent/JP6017728B2/ja active Active
- 2014-04-25 EP EP14720946.4A patent/EP2989088B1/en active Active
- 2014-04-25 CA CA3130994A patent/CA3130994A1/en active Pending
- 2014-04-25 LT LTEP14720946.4T patent/LT2989088T/lt unknown
- 2014-04-25 RS RS20181410A patent/RS58161B1/sr unknown
- 2014-04-25 RU RU2015147447A patent/RU2015147447A/ru unknown
- 2014-04-25 HU HUE18172389A patent/HUE058167T2/hu unknown
- 2014-04-25 RU RU2015146957A patent/RU2015146957A/ru unknown
- 2014-04-25 KR KR1020217012000A patent/KR102389167B1/ko not_active Expired - Fee Related
- 2014-04-25 UA UAA201511563A patent/UA115806C2/uk unknown
- 2014-04-25 SI SI201430953T patent/SI2989086T1/sl unknown
- 2014-04-25 ES ES14719328.8T patent/ES2693368T3/es active Active
- 2014-04-25 MA MA38583A patent/MA38583B1/fr unknown
2015
- 2015-09-28 TN TN2015000439A patent/TN2015000439A1/en unknown
- 2015-10-20 IL IL242184A patent/IL242184A/en active IP Right Grant
- 2015-10-22 SA SA515370043A patent/SA515370043B1/ar unknown
- 2015-11-19 ZA ZA2015/08545A patent/ZA201508545B/en unknown
2017
- 2017-09-19 US US15/708,685 patent/US20180222858A1/en not_active Abandoned
- 2017-12-15 CY CY20171101313T patent/CY1119677T1/el unknown
2018
- 2018-11-15 CY CY181101213T patent/CY1120863T1/el unknown
2019
- 2019-05-30 US US16/426,532 patent/US20200010414A1/en not_active Abandoned
2020
- 2020-10-27 US US17/081,162 patent/US20210107868A1/en not_active Abandoned
2022
- 2022-08-11 US US17/819,089 patent/US20230002316A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MA38583B1 (fr)	2018-11-30
WO2014174064A1 (en)	2014-10-30
JP2016519114A (ja)	2016-06-30
PT2989086T (pt)	2018-11-29
RU2015147447A (ru)	2017-05-31
LT2989088T (lt)	2018-01-10
KR20210046871A (ko)	2021-04-28
NO2989088T3 (pl)	2018-02-24
HK1215867A1 (zh)	2016-09-23
US20160068566A1 (en)	2016-03-10
US20160083420A1 (en)	2016-03-24
FR3005051A1 (fr)	2014-10-31
HUE035180T2 (hu)	2018-05-02
BR112015026410B1 (pt)	2022-06-07
CN105408318A (zh)	2016-03-16
KR101640361B1 (ko)	2016-07-15
CA3130994A1 (en)	2014-10-30
MA38583A1 (fr)	2018-07-31
WO2014174062A1 (en)	2014-10-30
JP6017728B2 (ja)	2016-11-02
AU2014259431B2 (en)	2017-02-02
EP2989087A1 (en)	2016-03-02
MY177702A (en)	2020-09-23
LT2989086T (lt)	2018-11-26
US20180222858A1 (en)	2018-08-09
CN105143199A (zh)	2015-12-09
MX372911B (es)	2020-04-27
ES2654364T3 (es)	2018-02-13
SA515370043B1 (ar)	2018-01-24
AU2014259431A1 (en)	2015-12-03
BR112015026410A2 (pt)	2017-07-25
CN105377834A (zh)	2016-03-02
KR102368136B1 (ko)	2022-02-25
SI2989086T1 (sl)	2018-12-31
MX2015014941A (es)	2016-03-07
KR20160003735A (ko)	2016-01-11
UA115806C2 (uk)	2017-12-26
KR20160003734A (ko)	2016-01-11
DK2989088T3 (en)	2017-12-18
US20200010414A1 (en)	2020-01-09
DK3388427T3 (da)	2022-03-07
EP2989086B1 (en)	2018-08-22
CY1120863T1 (el)	2019-12-11
CA2910178A1 (en)	2014-10-30
BR112015026565A2 (pt)	2017-07-25
CN105377834B (zh)	2018-04-20
CY1119677T1 (el)	2018-04-04
EP3388427A1 (en)	2018-10-17
US20230002316A1 (en)	2023-01-05
NZ714203A (en)	2020-05-29
AU2014259427B2 (en)	2018-04-05
MX2015014746A (es)	2016-03-04
TN2015000439A1 (en)	2017-01-03
BR112015026478A2 (pt)	2017-07-25
MX2015014831A (es)	2016-08-03
ES2908224T3 (es)	2022-04-28
JP2016520041A (ja)	2016-07-11
DK2989086T3 (en)	2018-11-12
CA2910176C (en)	2021-11-09
RS56717B1 (sr)	2018-03-30
JP2016519115A (ja)	2016-06-30
HK1215580A1 (zh)	2016-09-02
TN2015000445A1 (en)	2017-04-06
RS58161B1 (sr)	2019-03-29
WO2014174060A1 (en)	2014-10-30
AU2014259427A1 (en)	2015-11-19
HRP20171977T1 (hr)	2018-02-09
JP6606489B2 (ja)	2019-11-13
US20160068567A1 (en)	2016-03-10
EP2989086A1 (en)	2016-03-02
CA2909126A1 (en)	2014-10-30
EP2989088B1 (en)	2017-09-27
HUE040431T2 (hu)	2019-03-28
KR102389167B1 (ko)	2022-04-20
RU2015149527A (ru)	2017-05-29
MX345126B (es)	2017-01-17
RU2015146957A (ru)	2017-05-31
PT2989088T (pt)	2018-01-03
AU2014259429A1 (en)	2015-11-12
EP3388427B1 (en)	2022-01-19
EP2989088A1 (en)	2016-03-02
RU2662951C2 (ru)	2018-07-31
HUE058167T2 (hu)	2022-07-28
ES2693368T3 (es)	2018-12-11
PL2989086T3 (pl)	2019-02-28
SI2989088T1 (en)	2018-02-28
KR20160003003A (ko)	2016-01-08
ZA201508545B (en)	2017-07-26
US20210107868A1 (en)	2021-04-15
IL242184A (en)	2017-09-28
CA2910176A1 (en)	2014-10-30
HRP20181890T1 (hr)	2019-01-11
PL3388427T3 (pl)	2022-05-09

Publication	Publication Date	Title
ZA201508545B (en)	2017-07-26	Derivatives of dolastatin 10 and auristatins
IL273090B (en)	2022-06-01	Methods and preparations for the treatment of cancer
IL248961A0 (en)	2017-01-31	Oristatin histories and their conjugations
EP3043824A4 (en)	2017-10-25	Modified therapeutic agents and compositions thereof
IL265876A (en)	2019-06-30	Preparations that include 15-ohepa and methods of using them
SG10201708595YA (en)	2017-11-29	Cenicriviroc compositions and methods of making and using the same
IL249394A0 (en)	2017-02-28	Anti-cd22 drug-antibody conjugates and methods of using them
IL259186A (en)	2018-07-31	Anti-cd22-maytensin antibody conjugates and methods of using them
PL2968478T3 (pl)	2019-01-31	Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP2994147A4 (en)	2017-03-08	Compositions and methods for the treatment of tinnitus
GB201307082D0 (en)	2013-05-29	Pharmaceutical composition comprising 15-HETrE and methods of using the same
HUE050547T2 (hu)	2020-12-28	Oligoszaccharid konjugátumok és alkalmazási eljárások
TH1501006461A (th)	2017-10-19	อนุพันธ์ของโดลาสแททิน 10 และออริสแททิน (Derivatives of dolastatin 10 and auristatins)
GB201300628D0 (en)	2013-02-27	Compositions comprising 15-OHEPA and methods of using the same
AU2014315422A1 (en)	2015-03-12	Rilyazine derivatives and compositions for the treatment of cancer
AU2013901658A0 (en)	2013-05-30	Compositions and methods for the treatment of tinnitus